Close

J&J to supply COVID-19 vaccines to African Union - expert comment from Peter Piot

The pharmaceutical company Johnson & Johnson (J&J) has announced it will supply up to 400 million doses of its COVID-19 vaccine to the African Union.
Professor Peter Piot: "I hope this is a catalyst for further action that ensures fair and equitable access to successful COVID-19 vaccines, one of the most urgent issues we face in this pandemic."

J&J unit Janssen Pharmaceutica NV has entered into a deal with the African Vaccine Acquisition Trust (AVAT) to deliver up to 400 million doses of its single-dose shot through 2022. These supplies will help the continent reach its target of vaccinating at least 60% of the population, as it tries to contain the spread of the virus. 

Professor Peter Piot, Director of the London School of Hygiene & Tropical Medicine, reacts:

“I’m thrilled at this agreement between J&J and the African Union which is a game-changing moment in Africa’s response to the COVID-19 pandemic. 

“Combined with the vaccines supplied through COVAX for low and middle income countries, this deal should ensure all African adults will receive a COVID19 vaccine.

"While fantastic news for Africans, saving lives and livelihoods throughout the continent, it is also a vital deal for the rest of the world. The pandemic is not over until it’s over everywhere.

"I hope this agreement is a catalyst for further action that ensures fair and equitable access to successful COVID-19 vaccines, one of the most urgent issues we face in this pandemic.” 

Fee discounts

Our postgraduate taught courses provide health practitioners, clinicians, policy-makers, scientists and recent graduates with a world-class qualification in public and global health.

If you are coming to LSHTM to study an intensive master's degree or distance learning programme (PG Cert, PG Dip, MSc or individual modules) starting in 2024, you may be eligible for a 5% discount on your tuition fees.

These fee reduction schemes are available for a limited time only.